Interchangeability In Biosimilars : vimarsana.com

Maia Kayal, MD, MS, defines interchangeability and reviews the requirements from the FDA, "switching studies," and meaningful difference verses class effect.

Related Keywords

Maia Kayal , , Biosimilars Stakeholder Summit , Interchangeable Biosimilars , Inflammatory Diseases , Interchangeability , Biosimilars , Fda Requirements , Pharmacy Level , Interchangeable Designation , Reference Product , Switching Study , Meaningful Difference , Class Effect , Designation ,